Through a $75 million investment over at least five years, the American Heart Association (AHA), Verily and AstraZeneca are embarking on a groundbreaking research enterprise to prevent and/or reverse coronary heart disease and its consequences.
This is the single largest research project funding one leader and team in the fight to cure coronary heart disease – as well as the most accessible: anyone who believes they have the idea and capabilities to lead a team that can end coronary heart disease and improve cardiovascular health is eligible to apply. The application period is open from Jan. 14–Feb. 14, 2016. Ultimately, the applicant who demonstrates an ability to lead a diverse team of experts, with the most visionary and bold idea, will be the selected leader and awarded the opportunity and challenge to bring this vision to life.
AHA, Verily and AstraZeneca are looking for the one brave idea from a leader with the vision and capability of creating a diverse team of the world’s best and brightest minds. This team will be provided with unprecedented technical, scientific, medical, and financial resources so that they can solve one of the world’s greatest health challenges.
The ultimate goal is to design and implement novel strategies to prevent or reverse the causes and drivers of coronary heart disease, thereby restoring cardiovascular health to patients helping to enhance longevity and improve quality of life around the world.
Traditional research funding models are often incremental and piecemeal and make it difficult to study a long-term, multifaceted subject. Branded as One Brave Idea™, this approach is a fundamentally different kind of model for funding innovation – it is designed to remove the barriers and the silos that plague traditional research projects.
One Brave Idea™ seeks to uncover the drivers of coronary heart disease with an inclusive focus on causative factors and consequences and ultimately to end the disease. Visit www.onebraveidea.com to submit your idea by 11:59 p.m. CT on Feb. 14, 2016.